drugset
drugset / Trial / NCT01299142

Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6)

NCT01299142 ↗

Phase 1 Unknown 48 enrolled Functional Genetics Inc. United States Department of Defense · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to determine the safety and tolerability of the anti-TSG101 human monoclonal antibody (FGI-101-1A6)when administered intravenously to healthy volunteers.

Timeline

Start
2011-01
Primary completion
2011-07
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject FGI-101-1A6 Monoclonal antibody — Intravenous

Indications

influenza